Drug Search Results
More Filters [+]

Caricotamide

Alternative Names: caricotamide
Latest Update: 2016-06-09
Latest Update Note: Clinical Trial Update

Product Description

Caricotamide is a synthetic co-substrate that activates the human endogenous enzyme NRH:quinone oxidoreductase 2 (NQO2) with potential chemoadjuvant activity (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Caricotamide)

Mechanisms of Action: QOR Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Protherics Development Medicines Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Caricotamide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PR003-CLN-pro001

P2

Terminated

Hepatocellular Carcinoma

2009-06-01

2008-000912-34

P2

Completed

Hepatocellular Carcinoma

2009-03-05

Recent News Events

Date

Type

Title